JP2010527919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527919A5 JP2010527919A5 JP2010507463A JP2010507463A JP2010527919A5 JP 2010527919 A5 JP2010527919 A5 JP 2010527919A5 JP 2010507463 A JP2010507463 A JP 2010507463A JP 2010507463 A JP2010507463 A JP 2010507463A JP 2010527919 A5 JP2010527919 A5 JP 2010527919A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein complex
- soluble
- polypeptide
- soluble fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 77
- 108020001507 fusion proteins Proteins 0.000 claims 77
- 102000003812 Interleukin-15 Human genes 0.000 claims 55
- 108090000172 Interleukin-15 Proteins 0.000 claims 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 229920001184 polypeptide Polymers 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 210000004027 cell Anatomy 0.000 claims 22
- 108091008874 T cell receptors Proteins 0.000 claims 20
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 20
- 150000001413 amino acids Chemical class 0.000 claims 16
- 238000006467 substitution reaction Methods 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 239000002609 medium Substances 0.000 claims 11
- 230000027455 binding Effects 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 7
- 108020003175 receptors Proteins 0.000 claims 7
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 6
- 102000056003 human IL15 Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 102000009058 Death Domain Receptors Human genes 0.000 claims 1
- 108010049207 Death Domain Receptors Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 108010053727 Interleukin-15 Receptor alpha Subunit Proteins 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 108091008034 costimulatory receptors Proteins 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 230000014621 translational initiation Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92890007P | 2007-05-11 | 2007-05-11 | |
| US60/928,900 | 2007-05-11 | ||
| PCT/US2008/005918 WO2008143794A1 (en) | 2007-05-11 | 2008-05-09 | Fusion molecules and il-15 variants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014009393A Division JP5841623B2 (ja) | 2007-05-11 | 2014-01-22 | 融合分子及びｉｌ−１５変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010527919A JP2010527919A (ja) | 2010-08-19 |
| JP2010527919A5 true JP2010527919A5 (https=) | 2011-06-23 |
| JP5501222B2 JP5501222B2 (ja) | 2014-05-21 |
Family
ID=40122019
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507463A Active JP5501222B2 (ja) | 2007-05-11 | 2008-05-09 | 融合分子及びｉｌ−１５変異体 |
| JP2014009393A Active JP5841623B2 (ja) | 2007-05-11 | 2014-01-22 | 融合分子及びｉｌ−１５変異体 |
| JP2015222615A Active JP6152156B2 (ja) | 2007-05-11 | 2015-11-13 | 融合分子及びｉｌ−１５変異体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014009393A Active JP5841623B2 (ja) | 2007-05-11 | 2014-01-22 | 融合分子及びｉｌ−１５変異体 |
| JP2015222615A Active JP6152156B2 (ja) | 2007-05-11 | 2015-11-13 | 融合分子及びｉｌ−１５変異体 |
Country Status (10)
| Country | Link |
|---|---|
| US (11) | US8492118B2 (https=) |
| EP (4) | EP2769984B1 (https=) |
| JP (3) | JP5501222B2 (https=) |
| CN (3) | CN101743249B (https=) |
| AU (1) | AU2008253720B2 (https=) |
| CA (2) | CA2690825C (https=) |
| DK (3) | DK2160401T3 (https=) |
| ES (3) | ES2642008T3 (https=) |
| PT (3) | PT2769984T (https=) |
| WO (1) | WO2008143794A1 (https=) |
Families Citing this family (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3263581B2 (en) | 2005-05-17 | 2025-07-09 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
| KR101492643B1 (ko) | 2005-12-02 | 2015-02-12 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도 |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| NZ582330A (en) | 2007-06-27 | 2012-05-25 | Marinepolymer Tech Inc | COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF |
| EP2406289B1 (en) | 2009-03-10 | 2017-02-22 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| DK2406286T3 (en) | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40 antibodies and uses thereof |
| EP2258719A1 (en) * | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| WO2011020047A1 (en) | 2009-08-14 | 2011-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| US8592364B2 (en) * | 2010-02-11 | 2013-11-26 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | CCR7 ligand delivery and co-delivery in immunotherapy |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| CN107880136B (zh) * | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| WO2018112219A1 (en) * | 2016-12-14 | 2018-06-21 | Nant Holdings Ip, Llc | Superkine |
| CA2815000C (en) * | 2010-10-22 | 2024-05-21 | Dana-Farber Cancer Institute, Inc. | Discovery of regulatory t cells programmed to suppress an immune response |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| SG10201609500QA (en) | 2012-02-15 | 2016-12-29 | Ecole Polytech | Erythrocyte-binding therapeutics |
| WO2014023315A1 (en) | 2012-08-10 | 2014-02-13 | Aarhus Universitet | Multimerization through beta-strand swapping in ccp domains |
| WO2014052545A2 (en) | 2012-09-28 | 2014-04-03 | Dana-Farber Cancer Institute, Inc. | Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis |
| NZ630790A (en) | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| EA038981B1 (ru) | 2013-03-14 | 2021-11-17 | Икан Скул Оф Медсин Эт Маунт Синай | Вирусы болезни ньюкасла и их применение |
| DK2986312T3 (da) | 2013-04-19 | 2022-02-14 | Cytune Pharma | Cytokinafledt behandling med reduceret vaskulært lækagesyndrom |
| CA2918119C (en) * | 2013-07-19 | 2022-11-29 | Centre Hospitalier Regional Universitaire De Montpellier | Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases |
| BR112016002614B8 (pt) | 2013-08-08 | 2023-11-07 | Hopitaux Paris Assist Publique | Imunocitoquina e composição farmacêutica |
| JP7037884B2 (ja) | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| KR102717969B1 (ko) | 2014-02-21 | 2024-10-15 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 글리코타겟팅 치료제 |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| WO2015127501A1 (en) | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| WO2015164107A1 (en) | 2014-04-23 | 2015-10-29 | Emory University | Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto |
| CA3151221C (en) | 2014-06-30 | 2026-01-13 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| WO2016018920A1 (en) | 2014-07-29 | 2016-02-04 | Admune Therapeutics Llc | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
| AU2015308899B2 (en) | 2014-08-27 | 2020-05-28 | Dana-Farber Cancer Institute, Inc. | Intracellular osteopontin regulates the lineage commitment of lymphoid subsets |
| WO2016060996A2 (en) * | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| AU2015366795B2 (en) * | 2014-12-19 | 2020-12-17 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukin 15 protein complex and use thereof |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| US12577323B2 (en) | 2015-06-10 | 2026-03-17 | Emory University | Compositions and conjugates comprising an interleukin and polypeptides that specifically bind TGF-beta |
| EP3350205A1 (en) * | 2015-09-16 | 2018-07-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| KR20180125435A (ko) * | 2015-09-25 | 2018-11-23 | 알토 바이오사이언스 코포레이션 | 이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트 |
| WO2017059900A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| CA3017813C (en) * | 2016-03-17 | 2021-12-07 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2017177063A1 (en) * | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| AU2017271593B2 (en) * | 2016-05-27 | 2021-04-22 | Altor Bioscience Corporation | Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| WO2018013855A2 (en) | 2016-07-14 | 2018-01-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| CN118562016A (zh) * | 2016-10-21 | 2024-08-30 | 艾尔特生物科技公司 | 基于多聚体il-15的分子 |
| CN108250302A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多功能蛋白质 |
| CN108250301A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多靶点嵌合抗原受体 |
| US20200237874A1 (en) | 2017-01-20 | 2020-07-30 | Novartis Ag | Combination therapy for the treatment of cancer |
| RU2019122408A (ru) | 2017-01-20 | 2021-02-20 | Новартис Аг | Средство комбинированной терапии для лечения рака |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN117986384A (zh) | 2017-03-06 | 2024-05-07 | 艾尔特生物科技公司 | 与il-12和il-18的基于il-15的融合物 |
| WO2018166589A1 (en) | 2017-03-15 | 2018-09-20 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2018229706A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CA3066465A1 (en) | 2017-06-20 | 2018-12-27 | Nantkwest, Inc. | Nk-92 cells and il-15 agonist combination therapy |
| JP2020524694A (ja) | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのＩＬ−１β結合性抗体 |
| CN118307674A (zh) | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| AU2018292618A1 (en) | 2017-06-27 | 2019-12-19 | Novartis Ag | Dosage regimens for anti-TIM-3 antibodies and uses thereof |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| EP3676289B1 (en) | 2017-08-28 | 2026-03-04 | Altor BioScience, LLC | Il-15-based fusions to il-7 and il-21 |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| TW201922291A (zh) | 2017-11-16 | 2019-06-16 | 瑞士商諾華公司 | 組合療法 |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| EP3727146A4 (en) * | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| RU2020128830A (ru) | 2018-02-02 | 2022-03-03 | Новартис Аг | Комбинация агониста sting и il-15/il-15rа для лечения рака |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CA3091857A1 (en) * | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| JP2021516045A (ja) | 2018-02-28 | 2021-07-01 | ファイザー・インク | Ｉｌ−１５バリアントおよびその使用 |
| JP2021514625A (ja) * | 2018-03-01 | 2021-06-17 | グリコトープ ゲーエムベーハー | 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| EA202092723A1 (ru) | 2018-05-09 | 2021-04-09 | Зе Юниверсити Оф Чикаго | Композиции и способы, касающиеся иммунной толерантности |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| AU2019359475A1 (en) | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| WO2020097556A1 (en) * | 2018-11-09 | 2020-05-14 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| CN113227138A (zh) | 2018-12-21 | 2021-08-06 | 诺华股份有限公司 | IL-1β结合抗体的用途 |
| BR112021011351A2 (pt) | 2018-12-21 | 2021-11-16 | Novartis Ag | Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| US20220241375A1 (en) | 2019-05-20 | 2022-08-04 | Cytune Pharma | Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases |
| US20220289838A1 (en) * | 2019-08-19 | 2022-09-15 | Nantong Yichen Biopharma. Co. Ltd. | Immunocytokine, Preparation for the Same, and Uses Thereof |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| RU2753282C2 (ru) * | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| TW202128191A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | Tim-3抑制劑及其用途 |
| CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
| CN111690069B (zh) * | 2019-11-13 | 2022-04-19 | 中国科学技术大学 | 一种IL-15/SuIL-15Rα-mFc-γ4复合体蛋白及其构造方法、应用 |
| US20210188933A1 (en) * | 2019-12-18 | 2021-06-24 | Nantcell, Inc | Methods of treating pancytopenia |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| JP2023510393A (ja) | 2020-01-17 | 2023-03-13 | ノバルティス アーゲー | 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ |
| US20210244821A1 (en) * | 2020-02-05 | 2021-08-12 | Novartis Ag | Cho cell expressed het il-15 |
| IL297326A (en) | 2020-04-22 | 2022-12-01 | Novartis Ag | Pharmaceutical preparations and pharmaceutical products of human interleukin-15 hydrometers (ethyl-15) |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| CN114057889B (zh) * | 2020-07-30 | 2023-11-10 | 深圳市北科生物科技有限公司 | 二硫键稳定的IL15-IL15Rα复合物及其应用 |
| KR20250140647A (ko) | 2020-08-03 | 2025-09-25 | 난트셀, 인크. | Il-15 초작용제에 대한 약물-특이적 약동학 검정 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| MX2023004880A (es) | 2020-10-26 | 2023-05-11 | Cytune Pharma | AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA. |
| EP4232069A1 (en) | 2020-10-26 | 2023-08-30 | Cytune Pharma | Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| EP4271817A2 (en) | 2020-12-30 | 2023-11-08 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| CN117597355A (zh) | 2021-06-23 | 2024-02-23 | 赛腾制药 | 白细胞介素15变体 |
| CA3227386A1 (en) * | 2021-07-28 | 2023-02-02 | Jianing Huang | Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| JP7835868B2 (ja) | 2022-01-22 | 2026-03-25 | ナントセル，インコーポレーテッド | Ｃｔｌａ４及びｉｌ－１５の融合分子 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| GB202315149D0 (en) | 2023-10-03 | 2023-11-15 | Celleron Therapeutics Ltd | Combination therapy |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| US12605349B2 (en) | 2024-09-05 | 2026-04-21 | Orbus Therapeutics, Inc. | Methods of treating grade 3 astrocytoma |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS551222U (https=) | 1978-06-15 | 1980-01-07 | ||
| JPS5841623U (ja) | 1981-09-17 | 1983-03-18 | 日産デイ−ゼル工業株式会社 | リアエンジンバスにおけるエンジンル−ムの冷却及び房内熱風排出装置 |
| JPS6152156U (https=) | 1984-09-12 | 1986-04-08 | ||
| JPS6251570U (https=) | 1985-09-18 | 1987-03-31 | ||
| JPS648039U (https=) | 1987-06-29 | 1989-01-17 | ||
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5288931A (en) | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| WO1994004689A1 (en) | 1992-08-14 | 1994-03-03 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant toxin with increased half-life |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| JPH09512165A (ja) * | 1994-04-06 | 1997-12-09 | イミュネックス・コーポレーション | インターロイキン１５ |
| PT772624E (pt) | 1994-04-06 | 2001-03-30 | Immunex Corp | Interleucina-15 |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) * | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| DE69733610T2 (de) | 1996-04-26 | 2006-05-11 | Beth Israel Deaconess Medical Center, Inc., Boston | Interleukin-15 antagonisten |
| DK1273304T4 (da) | 1997-02-21 | 2009-08-31 | Amgen Inc | Anvendelse af interleukin-15 |
| GB9912350D0 (en) | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| BR0110779A (pt) * | 2000-05-12 | 2005-01-11 | Beth Israel Hospital | Composições e métodos para adquirir supressão imunológica |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| ATE427318T1 (de) | 2000-09-14 | 2009-04-15 | Beth Israel Hospital | Modulierung von il-2 und il-15 vermittelten t zellantworten |
| US20030180888A1 (en) * | 2000-11-03 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | CD2000 and CD2001 molecules, and uses thereof |
| FI117667B (fi) | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| EP1532175B1 (en) | 2002-03-22 | 2012-10-17 | Aprogen, Inc. | Humanized antibody and process for preparing the same |
| US20040156826A1 (en) * | 2002-09-27 | 2004-08-12 | Fernando Dangond | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| ZA200506724B (en) | 2003-02-26 | 2007-03-28 | Genmab As | Human antibodies specific for interleukin 15 (IL-15) |
| DE10324708A1 (de) | 2003-05-30 | 2004-12-16 | Ltn Servotechnik Gmbh | Schleifringelement und Verfahren zu dessen Herstellung |
| CN1233822C (zh) | 2003-09-05 | 2005-12-28 | 中国科学技术大学 | 白细胞介素－15基因修饰的自然杀伤细胞株及其制备方法 |
| US8772451B2 (en) | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| EP1718670B1 (en) * | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| EP1586585A1 (de) | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
| CN100334112C (zh) | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| WO2006065495A2 (en) | 2004-11-24 | 2006-06-22 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| MX2007006832A (es) * | 2004-12-13 | 2007-08-07 | Cytos Biotechnology Ag | Arreglos de antigeno interleucina 15 y usos de los mismos. |
| EP3263581B2 (en) | 2005-05-17 | 2025-07-09 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| DK1873166T3 (da) | 2006-06-30 | 2010-12-20 | Conaris Res Inst Ag | Forbedrede sgp 130Fc-dimerer |
| US7965180B2 (en) | 2006-09-28 | 2011-06-21 | Semiconductor Energy Laboratory Co., Ltd. | Wireless sensor device |
| CA2682527C (en) | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| AU2013273643C1 (en) | 2007-05-11 | 2016-08-11 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| JP2010530895A (ja) | 2007-06-21 | 2010-09-16 | アンジェリカ セラピューティックス，インク． | 修飾毒素 |
| NZ582330A (en) | 2007-06-27 | 2012-05-25 | Marinepolymer Tech Inc | COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF |
| WO2009117117A1 (en) * | 2008-03-19 | 2009-09-24 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use there of |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| CN107880136B (zh) | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US20130302274A1 (en) | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| NZ630790A (en) | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| US8977012B2 (en) | 2012-10-31 | 2015-03-10 | Google Inc. | Image denoising system and method |
| SI3094351T1 (sl) | 2014-01-15 | 2022-05-31 | Kadmon Corporation, Llc | Imunomodulatorna sredstva |
| CA3151221C (en) | 2014-06-30 | 2026-01-13 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| CN104672325A (zh) | 2015-03-11 | 2015-06-03 | 福建农林大学 | 一种用新鲜螺旋藻制备藻蓝蛋白的方法 |
| KR20180125435A (ko) | 2015-09-25 | 2018-11-23 | 알토 바이오사이언스 코포레이션 | 이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트 |
| AU2017271593B2 (en) | 2016-05-27 | 2021-04-22 | Altor Bioscience Corporation | Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains |
| CN118562016A (zh) | 2016-10-21 | 2024-08-30 | 艾尔特生物科技公司 | 基于多聚体il-15的分子 |
| CN117986384A (zh) * | 2017-03-06 | 2024-05-07 | 艾尔特生物科技公司 | 与il-12和il-18的基于il-15的融合物 |
| EP3676289B1 (en) * | 2017-08-28 | 2026-03-04 | Altor BioScience, LLC | Il-15-based fusions to il-7 and il-21 |
| TW202003011A (zh) | 2018-03-26 | 2020-01-16 | 美商艾爾特生物科技責任有限公司 | 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子 |
-
2008
- 2008-05-09 DK DK08743432.0T patent/DK2160401T3/da active
- 2008-05-09 CN CN200880024119.5A patent/CN101743249B/zh active Active
- 2008-05-09 CA CA2690825A patent/CA2690825C/en active Active
- 2008-05-09 AU AU2008253720A patent/AU2008253720B2/en active Active
- 2008-05-09 CN CN201410242394.1A patent/CN104109200B/zh active Active
- 2008-05-09 DK DK14162248.0T patent/DK2769984T3/en active
- 2008-05-09 ES ES14162248.0T patent/ES2642008T3/es active Active
- 2008-05-09 ES ES11178091.2T patent/ES2470772T3/es active Active
- 2008-05-09 ES ES08743432.0T patent/ES2518393T3/es active Active
- 2008-05-09 WO PCT/US2008/005918 patent/WO2008143794A1/en not_active Ceased
- 2008-05-09 JP JP2010507463A patent/JP5501222B2/ja active Active
- 2008-05-09 US US12/151,980 patent/US8492118B2/en active Active
- 2008-05-09 EP EP14162248.0A patent/EP2769984B1/en active Active
- 2008-05-09 CA CA3028038A patent/CA3028038C/en active Active
- 2008-05-09 PT PT141622480T patent/PT2769984T/pt unknown
- 2008-05-09 PT PT111780912T patent/PT2388266E/pt unknown
- 2008-05-09 CN CN201810136797.6A patent/CN108948177B/zh active Active
- 2008-05-09 PT PT87434320T patent/PT2160401E/pt unknown
- 2008-05-09 EP EP11178091.2A patent/EP2388266B1/en active Active
- 2008-05-09 EP EP17187942.2A patent/EP3305805A1/en not_active Withdrawn
- 2008-05-09 EP EP08743432.0A patent/EP2160401B1/en active Active
- 2008-05-09 DK DK11178091.2T patent/DK2388266T3/da active
-
2010
- 2010-02-05 US US12/700,949 patent/US8163879B2/en active Active
-
2012
- 2012-03-23 US US13/428,776 patent/US8940289B2/en active Active
-
2013
- 2013-07-19 US US13/946,438 patent/US9464127B2/en active Active
-
2014
- 2014-01-22 JP JP2014009393A patent/JP5841623B2/ja active Active
- 2014-12-12 US US14/568,573 patent/US9593152B2/en active Active
-
2015
- 2015-11-13 JP JP2015222615A patent/JP6152156B2/ja active Active
-
2016
- 2016-09-01 US US15/254,713 patent/US10450359B2/en active Active
-
2019
- 2019-10-16 US US16/654,958 patent/US11365231B2/en active Active
- 2019-10-21 US US16/659,311 patent/US11498950B1/en active Active
-
2022
- 2022-04-08 US US17/716,986 patent/US11673932B2/en active Active
-
2023
- 2023-04-24 US US18/305,965 patent/US12168680B2/en active Active
-
2024
- 2024-10-31 US US18/933,787 patent/US20250066442A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010527919A5 (https=) | ||
| JP2020191862A5 (https=) | ||
| JP2020198875A5 (https=) | ||
| AU2016341533B2 (en) | Methods for culturing cells and kits and apparatus for same | |
| TWI908730B (zh) | 識別p53中之r175h或y220c突變之t細胞受體 | |
| JP2021101700A5 (https=) | ||
| JP2024099580A5 (https=) | ||
| JP2013541335A5 (https=) | ||
| KR20180100110A (ko) | 세포의 배양 방법 및 이를 위한 키트와 장치 | |
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| WO2008039818A3 (en) | Modified t cell receptors and related materials and methods | |
| JP2020516681A5 (https=) | ||
| JP2018528786A5 (https=) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| RU2002103870A (ru) | Человеческое моноклональное антитело против AILIM, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение | |
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| HRP20210528T1 (hr) | Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma | |
| US20220195006A1 (en) | Peptide markers to track genetically engineered cells | |
| WO2006054096A2 (en) | Soluble bifunctional proteins | |
| JP2020191868A5 (https=) | ||
| JP2019504631A5 (https=) | ||
| JP2021045150A5 (https=) | ||
| HRP20192212T1 (hr) | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova | |
| CA3134692A1 (en) | Binding molecules specfic for hbv envelope protein | |
| JPWO2020058285A5 (https=) |